Related references
Note: Only part of the references are listed.Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide
Susan F. Murphy et al.
CANCER RESEARCH (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wolfgang Wick et al.
CLINICAL CANCER RESEARCH (2016)
Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line
Guo-zhong Yi et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2016)
ER stress in temozolomide-treated glioblastomas interferes with DNA repair and induces apoptosis
Jessica L. Weatherbee et al.
ONCOTARGET (2016)
Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells
Jessian L. Munoz et al.
CANCER LETTERS (2015)
Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide
Jose L. McFaline-Figueroa et al.
CANCER RESEARCH (2015)
Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions
Michal Bienkowski et al.
CLINICAL NEUROPATHOLOGY (2015)
Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution
Hoon Kim et al.
GENOME RESEARCH (2015)
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance
Malin Wickstrom et al.
NATURE COMMUNICATIONS (2015)
Epidemiologic and Molecular Prognostic Review of Glioblastoma
Jigisha P. Thakkar et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
MGMT testing-the challenges for biomarker-based glioma treatment
Wolfgang Wick et al.
NATURE REVIEWS NEUROLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
David A. Nathanson et al.
SCIENCE (2014)
Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43
J. L. Munoz et al.
CELL DEATH & DISEASE (2014)
Understanding and Targeting Alkylator Resistance in Glioblastoma
Wolfgang Wick et al.
CANCER DISCOVERY (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival
Severina Leu et al.
NEURO-ONCOLOGY (2013)
Base Excision Repair
Hans E. Krokan et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients
Sameer Agnihotri et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients
Kai Tang et al.
MEDICAL ONCOLOGY (2012)
Temozolomide: Mechanisms of Action, Repair and Resistance
Jihong Zhang et al.
Current Molecular Pharmacology (2011)
Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
K. A. van Nifterik et al.
BRITISH JOURNAL OF CANCER (2010)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Activation of AMP-activated Protein Kinase by Temozolomide Contributes to Apoptosis in Glioblastoma Cells via p53 Activation and mTORC1 Inhibition
Wen-bin Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Michael Brada et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
New (alternative) temozolomide regimens for the treatment of glioma
Wolfgang Wick et al.
NEURO-ONCOLOGY (2009)
Mechanisms of chemoresistance to alkylating agents in malignant glioma
Jann N. Sarkaria et al.
CLINICAL CANCER RESEARCH (2008)
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
Paul D. Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents
Bernd Kaina et al.
DNA REPAIR (2007)
New approaches to molecular cancer therapeutics
Ian Collins et al.
NATURE CHEMICAL BIOLOGY (2006)
Targeted modulation of MGMT: Clinical implications
LL Liu et al.
CLINICAL CANCER RESEARCH (2006)
Drug Insight: temozolomide as a treatment for malignant glioma - impact of a recent trial
WP Mason et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2005)
The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death
RN Trivedi et al.
CANCER RESEARCH (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Navigating chemical space for biology and medicine
C Lipinski et al.
NATURE (2004)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
